Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand

ABSTRACT

Chromatography resins having mixed mode ligands and methods of using such resins are provided.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.16/967,429, filed Aug. 5, 2020, now allowed, which is the U.S. nationalstage application of International Patent Application No.PCT/US2019/016619, filed Feb. 5, 2019, which claims priority from U.S.Ser. No. 62/626,245, filed Feb. 5, 2018.

BACKGROUND

The extraction of immunoglobulins from source liquids, which areprimarily mammalian bodily fluids or cell culture harvest, is of valuein obtaining the immunoglobulins in a sufficiently concentrated orpurified form for diagnostic and therapeutic uses as well as laboratorystudies in general. Similarly, purification of other types of proteinsand other molecules from biological samples can be of value.

SUMMARY

Chromatography resins comprising chromatography matrices linked to ananionic exchange-hydrophobic mixed mode ligand are provided. In someembodiments, the chromatography resin has the formula:

Chromatography matrix-(X₁)-L-Ar-(X2)-Y

or a tautomer or an anionic salt thereof,wherein:

-   -   X₁ is a spacer;    -   X2 is C₁ to C₅ alkyl, C₃ or C₅ cycloalkyl, or absent;    -   L is NR⁸, O, or S, wherein R⁸ is hydrogen or C₁ to C₆ alkyl;    -   Ar is a 6- to 10-membered mono or bicylic ring and is aryl        optionally substituted with up to four C₁ to C₃ unsubstituted        alkyl or C₃ to C₆ branched alkyl; and        Y is selected from the group consisting of:

wherein:

-   -   R¹, R², R³, R⁴, R⁵, R⁶, and R⁷ are each independently hydrogen        or Ci to C6 alkyl;    -   if Y is

R² is optionally joined to R³ to form a 4- to 7-membered heterocycle orR³ is optionally joined to R⁴ to form a 4- to 7-membered heterocycle;

-   -   if Y is

R¹ is optionally joined to R² to form a 4- to 7-membered heterocycle andR³ is optionally joined to R⁴ to form a 4- to 7-membered heterocycle;and

-   -   if Y is

R⁵ is optionally joined to R⁶ to form a 4- to 7-membered heterocycle orR⁶ is optionally joined to R⁷ to form a 4- to 7-membered heterocycle.

In some embodiments of the chromatography resin:

X¹ is a spacer;X² is C₁-C₃ alkyl or absent;L is NR⁸, O, or S wherein R⁸ is hydrogen or C₁ to C₃ alkyl;Ar is phenyl or napthyl optionally substituted with up to four C₁ to C₃unsubstituted alkyl; andY is selected from the group consisting of:

wherein:

-   -   R¹, R², R³, R⁴, R⁵, R⁶, and R⁷ are each independently hydrogen        or C₁ to C₄ alkyl;    -   if Y is

R² is optionally joined to R³ to form a 4- to 6-membered heterocycle orR³ is optionally joined to R⁴ to form a 4- to 6-membered heterocycle;

-   -   if Y is

R¹ is optionally joined to R² to form a 4- to 6-membered heterocycle andR³ is optionally joined to R⁴ to form a 4- to 6-membered heterocycle;and

-   -   if Y is

R⁵ is optionally joined to R⁶ to form a 4- to 6-membered heterocycle orR⁶ is optionally joined to R⁷ to form a 4- to 6-membered heterocycle.

DETAILED DESCRIPTION

A linked chromatography resin that allows for efficient purification oftarget biomolecules from a sample is provided. Notably, the examplesillustrate that the linked chromatography resin is useful for separatingmonomeric antibodies from antibody aggregates in the sample.

Definitions

Unless otherwise stated, the following terms used in this application,including the specification and claims, have the definitions givenbelow. As used in this specification and the appended claims, thesingular forms “a”, “an”, and “the” include plural referents unless thecontent clearly dictates otherwise. Definition of standard chemistryterms can be found in reference works, including Carey and Sundberg(2007) “Advanced Organic Chemistry 5th Ed.” Vols. A and B, SpringerScience+Business Media LLC, New York. The practice of the presentinvention will employ, unless otherwise indicated, conventional methodsof synthetic organic chemistry, mass spectroscopy, preparative andanalytical methods of chromatography, protein chemistry, biochemistry,recombinant DNA techniques and pharmacology.

“Antibody” refers to an immunoglobulin, composite (e.g., fusion), orfragmentary form thereof. The term includes but is not limited topolyclonal or monoclonal antibodies of the classes IgA, IgD, IgE, IgG,and IgM, derived from human or other mammalian cell lines, includingnatural or genetically modified forms such as humanized, human,single-chain, chimeric, synthetic, recombinant, hybrid, mutated,grafted, and in vitro generated antibodies. “Antibody” also includescomposite forms including but not limited to fusion proteins containingan immunoglobulin moiety. “Antibody” also includes antibody fragmentssuch as Fab, F(ab′)2, Fv, scFv, Fd, dAb, Fc, whether or not they retainantigen-binding function.

As used herein, the term “alkyl” refers to a straight or branched,saturated, aliphatic radical having between 1-10 carbon atoms. Forexample, C₁-C₆ alkyl includes, but is not limited to, methyl, ethyl,propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl,isopentyl, and/or hexyl. Alkyl can include any number of carbons, suchas 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9, 1-10, 2-3, 2-4, 2-5, 2-6,3-4, 3-5, 3-6, 4-5, 4-6 and 5-6. The alkyl group is typicallymonovalent, but can be divalent, such as when the alkyl group links twochemical groups together.

As used herein, the term “cycloalkyl” refers to monocyclic alkyl havingthe number of carbon atoms indicated. Monocyclic rings include, forexample, cyclopropyl, cyclobutyl, and cyclopentyl.

As used herein, the term “aryl” refers to a monocyclic or fused bicyclicaromatic ring assembly. For example, aryl can be phenyl, naphthyl, orpyridyl. Aryl groups can optionally be substituted by one, two, three,or four unsubstituted alkyl groups.

As used herein, the term “heterocycle” refers to ring assemblies thatinclude one to three heteroatoms as a ring member. Examples include, butare not limited to, cyclic amines such as azetidino, pyrrolidino,piperidino, pyrazolidino, and imidazolidino. Heterocycles can optionallybe substituted by one, two, three, or four alkyl groups.

An “anionic salt” is formed at a basic (e.g., guanidine, amino oralkylamino) group in the ligands. Anionic salts include, but are notlimited to, halides, sulfonates, sulfates, carboxylates, phosphates,acetates, citrates and nitrates. Examples of acid-addition saltsinclude, but are not limited to, hydrochloride, hydrobromide,hydroiodide, sulfate, acetate, citrate, and nitrate.

As used herein, the term “spacer” refers to a molecule having 1-30 atomsselected from H, C, N, O and S. The spacer has a neutral charge and caninclude cyclic groups. The spacer links the chromatographic ligand tothe chromatography. The types of bonds used to link the spacer to thechromatography matrix include, but are not limited to, amides, amines,ethers, esters, carbamates, ureas, thioethers, thiocarbamates,thiocarbonate and thioureas. In some embodiments, the bonds used to linkthe spacer to the chromatography matrix are amines, ethers or amides.

“Biological sample” refers to any composition containing a targetmolecule of biological origin (a “biomolecule”) that is desired to bepurified. In some embodiments, the target molecule to be purified is anantibody or a non-antibody protein (e.g., hormones or enzymes).

“Bind-elute mode” refers to an operational approach to chromatography inwhich the buffer conditions are established so that target moleculesand, optionally undesired contaminants, bind to the ligand when thesample is applied to the ligand. Fractionation of the target can beachieved subsequently by changing the conditions such that the target iseluted from the support. In some embodiments, contaminants remain boundfollowing target elution. In some embodiments, contaminants eitherflow-through or are bound and eluted before elution of the target.

“Flow-through mode” refers to an operational approach to chromatographyin which the buffer conditions are established so that the targetmolecule to be purified flows through the chromatography supportcomprising the ligand, while at least some sample contaminants areselectively retained, thus achieving their removal from the sample.

Chromatography Ligands

In a first embodiment, a chromatography resin has the formula:

Chromatography matrix-(X¹)-L-Ar-(X²)-Y

or a tautomer or an anionic salt thereof,wherein:

-   -   X¹ is a spacer;    -   X² is C₁ to C₅ alkyl, C₃ or C₅ cycloalkyl, or absent;    -   L is NR⁸, O, or S, wherein R⁸ is hydrogen or C₁ to C₆ alkyl;    -   Ar is a 6- to 10-membered aryl mono or bicylic ring optionally        substituted with up to four C₁ to C₃ unsubstituted alkyl or C₃        to C₆ branched alkyl; and    -   Y is selected from the group consisting of:

-   -   wherein:        -   R¹, R², R³, R⁴, R⁵, R⁶, and R⁷ are each independently            hydrogen or C₁ to C₆ alkyl;        -   if Y is

R² is optionally joined to R³ to form a 4- to 7-membered heterocycle orR³ is optionally joined to R⁴ to form a 4- to 7-membered heterocycle;

if Y is

R¹ is optionally joined to R² to form a 4- to 7-membered heterocycle andR³ is optionally joined to R⁴ to form a 4- to 7-membered heterocycle;and

if Y is

R⁵ is optionally joined to R⁶ to form a 4- to 7-membered heterocycle orR⁶ is optionally joined to R⁷ to form a 4- to 7-membered heterocycle.

In a first aspect of the first embodiment, X² is C₁-C₃ alkyl or absent.Alternatively X² is C₁-C₂ alkyl or absent. In yet another alternative,X² is methyl or absent.

In a second aspect of the first embodiment, L is NR⁸ or O or NR⁸ or S.Alternatively, L is NR⁸ wherein R⁸ is hydrogen or C₁ to C₃ alkyl. In yetanother alternative, L is NH.

In a third aspect of the first embodiment, Ar is a six-membered aryloptionally substituted with one or two C₁ to C₃ unsubstituted alkyl.Alternatively, Ar is phenyl optionally substituted with one or two C₁ toC₃ unsubstituted alkyl. Alternatively, Ar is unsubstituted phenyl.

In a fourth aspect of the first embodiment, Y is

wherein R¹-R⁴ are each independently H or C₁-C₄ alkyl and R² isoptionally joined to R³ to form a 4- to 7-membered heterocycle or R³ isoptionally joined to R⁴ to form a 4- to 7-membered heterocycle.

Alternatively, Y is

wherein none of R¹-R⁴ form heterocycles and are each independently H orC₁-C₄ alkyl; each independently H or C₁-C₂ alkyl; or each H.

In a fifth aspect of the first embodiment, Y is

wherein R¹-R⁴ are each independently H or C₁-C₄ alkyl and R¹ isoptionally joined to R² to form a 4- to 7-membered heterocycle and R³ isoptionally joined to R⁴ to form a 4- to 7-membered heterocycle.

Alternatively Y is

wherein none of R¹-R⁴ form heterocycles and are each independently H orC₁-C₄ alkyl; each independently H or C₁-C₂ alkyl; or each H.

In a sixth aspect of the first embodiment, Y is

wherein R¹-R⁷ are each independently H or C₁-C₄ alkyl and wherein R⁵ isoptionally joined to R⁶ to form a 4- to 7-membered heterocycle or R⁶ isoptionally joined to R⁷ to form a 4- to 7-membered heterocycle.Alternatively, Y is

wherein none of R¹-R⁷ form heterocycles and are each independently H orC₁-C₄ alkyl; each independently H or C₁-C₂ alkyl; or each H.

In a seventh aspect of the first embodiment, X¹ is attached tochromatography matrix via a bond selected from an amide, amine, ether,ester, carbamate, urea, thioether, thiocarbamate, thiocarbonate andthiourea. Alternatively the bond is an amine, ether or amide.

In an eighth aspect of the first embodiment, X¹ is selected from thegroup consisting of —O—CH₂—, —O—CH₂—CH₂—, —O—CH₂—CH₂—CH₂—,—O—CH₂—CH₂—CH₂—CH₂—, —O—CH₂—CH(CH₂—OH)—(O—CH₂—CH(OH)—CH₂)₂—,—O—CH₂—CH₂—CH(CH₂—OH)—(O—CH₂—CH₂—CH(OH)—CH₂)₂—, —O—CH₂—CH(OH)—CH₂—,—O—CH₂—CH₂—CH(OH)—CH₂—CH₂—,—O—CH₂—CH(OH)—CH₂—O—CH₂—CH₂—CH₂—CH₂—O—CH₂—CH(OH)—CH₂—, and—CO—NH—C(CH₃)₂—CO—. X¹ is selected from the group consisting of —O—CH₂—,—O—CH₂—CH₂—, —O—CH₂—CH₂—CH₂—, —O—CH₂—CH₂—CH₂—CH₂—, and—O—CH₂—CH(CH₂—OH)—(O—CH₂—CH(OH)—CH₂)₂—.

In a second embodiment, the chromatography resin has the formula:

Chromatography matrix-(X¹)-L-Ar-(X²)-Y

or a tautomer or an anionic salt thereof,wherein:X¹ is a spacer;

-   -   X² is C₁-C₃ alkyl or absent;    -   L is NR⁸, O, or S wherein R⁸ is hydrogen or C₁ to C₃ alkyl;    -   Ar is phenyl or napthyl, optionally substituted with up to four        C₁ to C₃ unsubstituted alkyl; and    -   Y is selected from the group consisting of:

-   -   wherein:        -   R¹, R², R³, R⁴, R⁵, R⁶, and R⁷ are each independently            hydrogen or Ci to C4 alkyl;

if Y is

R² is optionally joined to R³ to form a 4- to 6-membered heterocycle orR³ is optionally joined to R⁴ to form a 4- to 6-membered heterocycle;

if Y is

R¹ is optionally joined to R² to form a 4- to 6-membered heterocycle andR³ is optionally joined to R⁴ to form a 4- to 6-membered heterocycle;and

if Y is

R⁵ is optionally joined to R⁶ to form a 4- to 6-membered heterocycle orR⁶ is optionally joined to R⁷ to form a 4- to 6-membered heterocycle.

In a first aspect of the second embodiment, X² is C₁-C₂ alkyl or absent.In yet another alternative, X² is methyl or absent.

In a second aspect of the second embodiment, L is NR⁸ or O or NR⁸ or S.Alternatively, L is NR⁸ wherein R⁸ is hydrogen or C₁ to C₃ alkyl. In yetanother alternative, L is NH.

In a third aspect of the second embodiment, Ar is optionally substitutedwith one or two C₁ to C₃ unsubstituted alkyl. Alternatively, Ar isphenyl optionally substituted with one or two C₁ to C₃ unsubstitutedalkyl. Alternatively, Ar is unsubstituted phenyl.

In a fourth aspect of the second embodiment, Y is

wherein R² is optionally joined to R³ to form a 4- to 6-memberedheterocycle or R³ is optionally joined to R4 to form a 4- to 6-memberedheterocycle. Alternatively, Y is

wherein none of R¹-R⁴ form heterocycles and are each independently H orC₁-C₂ alkyl; or each H.

In a fifth aspect of the second embodiment, Y is

wherein R¹ is optionally joined to R² to form a 4- to 6-memberedheterocycle and R³ is optionally joined to R⁴ to form a 4- to 6-memberedheterocycle. Alternatively Y is

wherein none of R¹-R⁴ form heterocycles and are each independently H orC₁-C₂ alkyl; or each H.

In a sixth aspect of the second embodiment, Y is

wherein R⁵ is optionally joined to R⁶ to form a 4- to 6-memberedheterocycle or R⁶ is optionally joined to R⁷ to form a 4- to 6-memberedheterocycle. Alternatively, Y is

wherein none of R¹-R⁷ form heterocycles and are each independently H orC₁-C₂ alkyl; or each H.

In a seventh aspect of the second embodiment, X¹ is attached tochromatography matrix via a bond selected from an amide, amine, ether,ester, carbamate, urea, thioether, thiocarbamate, thiocarbonate andthiourea. Alternatively the bond is an amine, ether or amide.

In an eighth aspect of the second embodiment, X¹ is selected from thegroup consisting of —O—CH₂—, —O—CH₂—CH₂—, —O—CH₂—CH₂—CH₂—,—O—CH₂—CH₂—CH₂—CH₂—, —O—CH₂—CH(CH₂-OH)—(O—CH₂—CH(OH)—CH₂)₂—,—O—CH₂—CH₂—CH(CH₂—OH)—(O—CH₂—CH₂—CH(OH)—CH₂)₂—, —O—CH₂—CH(OH)—CH₂—,—O—CH₂—CH₂—CH(OH)—CH₂—CH₂—,—O—CH₂—CH(OH)—CH₂—O—CH₂—CH₂—CH₂—CH₂—O—CH₂—CH(OH)—CH₂—, and—CO—NH—C(CH₃)₂—CO—. Alternatively, X¹ is selected from the groupconsisting of —O—CH₂—, —O—CH₂—CH₂—, —O—CH₂—CH₂—CH₂—,—O—CH₂—CH₂—CH₂—CH₂—, and —O—CH₂—CH(CH₂—OH)—(O—CH₂—CH(OH)—CH₂)₂—

In a third embodiment, a chromatography resin has the formula:

Chromatography matrix-(X¹)-L-Ar-(X²)-Y

or a tautomer or an anionic salt thereof,wherein:

-   -   X¹ is a is selected from the group consisting of —O13 CH₂—,        —O—CH₂—CH₂—, —O—CH₂—CH₂—CH₂—, —O—CH₂—CH₂—CH₂—CH₂—,        —O—CH₂—CH(CH₂—OH)—(O—CH₂—CH(OH)—CH₂)₂—,        —O—CH₂—CH₂—CH₂—CH(CH₂—OH)—(O—CH₂—CH₂—CH(OH)—CH₂)₂—,        —O—CH₂—CH(OH)—CH₂—, —O—CH₂—CH₂—CH(OH)—CH₂—CH₂—,        —O—CH₂—CH(OH)—CH₂—O—CH2—CH₂—CH₂—CH₂—O—CH₂—CH(OH)—CH₂, and        —CO—NH—C(CH3)₂—CO—;    -   X² is —CH₂— or absent;    -   L is NR⁸ wherein R⁸ is hydrogen or —CH₃;    -   Ar is phenyl optionally substituted with one or two C₁ to C₂        unsubstituted alkyl; and    -   Y is selected from the group consisting of:

-   -   wherein:        -   R¹, R², R³, R⁴, R⁵, R⁶, and R⁷ are each independently            hydrogen or C₁ to C₃ alkyl.

In a first aspect of the third embodiment, L is NH.

In a second aspect of the third embodiment, Ar unsubstituted phenyl.

In a third aspect of the third embodiment, Y is

wherein R¹-R⁴ are each independently H or C₁-C₃ alkyl; or eachindependently H or C₁-C₂ alkyl; or each H.

In a fourth aspect of the third embodiment, Y is

wherein R¹-R⁴ are each independently H or C₁-C₂ alkyl; or each H.

In a fifth aspect of the third embodiment, Y is

wherein R¹-R⁷ are each independently H or C₁-C₂ alkyl; or each H.

In a sixth aspect of the third embodiment, X¹ is selected from the groupconsisting of —O—CH₂—, —O—CH₂—CH₂—, —O—CH₂—CH₂—CH₂—,—O—CH₂—CH₂—CH₂—CH₂—, and —O—CH₂—CH(CH₂—OH)—(O—CH₂—CH(OH)—CH₂)₂—.

In a fourth embodiment, chromatography matrix-(X¹)-L-Ar-(X²)-Y is anyone of the chromatography resin structures listed in the last column ofTable 1.

TABLE 1 Structure of Chromatography Num- Resin (spheres represent berLigand Name Ligand Structure matrix and spacer X¹) 1 1-(4- aminophenyl)guanidine

2 1-(4- aminobenzyl) guanidine

3 1-(4- aminophenyl- propyl) guanidine

4 1-(4- aminophenyl- butyl) guanidine

5 1-(4- aminophenyl- pentyl) guanidine

6 1-(4- aminophenyl- cyclopropyl) guanidine

7a 1-(4- ammophenyl- cyclobutyl) guanidine

7b

8a 1-(4- aminophenyl- cyclopentyl) guanidine

8b

9 3-(4- aminophenyl)- 1,1-dimethyl- guanidine

10 (4- aminobenzyl)- 1,1-dimethyl- guanidine

11 1-(4- aminophenyl- ethyl)guanidine

12 1-(amino(4- aminobenzyl) amino)methyl- guanidine

13 4-(((1,3- dimethyl- imidazolidin-2- ylidene)amino) methyl)aniline

14 2-(4- aminobenzyl)- 1,1,3,3- tetramethyl- guanidine

15 2-(4- aminophenyl)- 1,1,3,3- tetramethyl- guanidine

16 1-((6-amino- naphthalen- 2-yl)methyl) guanidine

17 N-(4- aminobenzyl) azetidine-1- carbox- imidamide

18 4-(((di (pyrrolidin-1- yl)methyl) amino)methyl) aniline

19 1-(4- aminobenzyl) 3- (imidazolidin- 2-ylidene) guanidine

20 N-(N-(4- aminobenzyl) carbamidoyl) azetidine-1- carbox- imidamide

21 1-(2- aminobenzyl) guanidine

22 1-(3- aminobenzyl) guanidine

In some embodiments, the salt is hydrochloride or sulfate.

The chromatography matrix is a polymer that is functionalized so that abond can be formed to the spacer, X¹. Preferably, the polymer is ahydrophilic polymer. The polymer is insoluble in water. Suitablepolymers are polyhydroxy polymers, e.g. based on polysaccharides, suchas agarose (e.g., Sepharose and Superose beads from GE Healthcare andBiogel A from Bio-Rad), dextran (e.g., Sephadex from GE Healthcare),cellulose, starch, pullulan, and completely synthetic polymers, such aspolyacrylic amide, polymethacrylic amide, poly(hydroxyalkylvinylethers), poly(hydroxyalkylacrylates) and polymethacrylates (e.g.polyglycidylmethacrylate), polyvinyl alcohols and polymers based onstyrenes and divinylbenzenes, and copolymers in which two or more of themonomers corresponding to the above-mentioned polymers are included.Suitable synthetic polymers include, but are not limited to, Fractogelfrom Toso-Haas, POROS media from ThermoFisher Scientific, Bio-Gel P andMacro Prep from Bio-Rad, HEMA and Separon from TESSEK, and Hyper D andTrisacryl media from Pall. Polymers, which are soluble in water, may bederivatized to become insoluble, e.g. by cross-linking and by couplingto an insoluble body via adsorption or covalent binding. Hydrophilicgroups can be introduced on hydrophobic polymers (e.g. on copolymers ofmonovinyl and divinylbenzenes) by polymerisation of monomers exhibitinggroups which can be converted to OH, or by hydrophilization of the finalpolymer, e.g. by adsorption of suitable compounds, such as hydrophilicpolymers. Examples of monomers that can be polymerized to achieve usefulmatrices are vinyl acetate, vinyl propylamine, acrylic acid,methacrylate, butyl acrylate, acrylamide, methacrylamide, vinylpyrrolidone (vinyl pyrrolidinone), with functional groups in some cases.Cross-linking agents are also of use in many embodiments, and whenpresent can in some embodiments constitute a mole ratio of from about0.1 to about 0.7 relative to total monomer. Examples of crosslinkingagents are dihydroxyethylenebisacrylamide, di allyltartardiamide,triallyl citric triamide, ethylene diacrylate, bisacrylylcystamine,N,N′-methylenebisacrylamide, and piperazine diacrylamide.

In some embodiments, the matrix is an UNOsphere™ support, a polymerproduced from water-soluble hydrophilic monomers (Bio-Rad, Hercules,Calif.).

The chromatography matrix can be in the form of a particle, chips, amembrane, or a monolith, i.e., a single block, pellet, or slab ofmaterial. Preferably, the chromatography matrix is porous. Particleswhen used as matrices can be spheres or beads and are eithersmooth-surfaced or with a rough or textured surface. In some cases, someof the pores are through-pores, extending through the particles to serveas channels large enough to permit hydrodynamic flow or fast diffusionthrough the pores. When in the form of spheres or beads, the medianparticle diameter, where the term “diameter” refers to the longestexterior dimension of the particle, is about 25 microns to about 150microns. Disclosures of exemplary matrices and the processes by whichthey are made are found in Hjertén et al., U.S. Pat. No. 5,645,717, Liaoet al., U.S. Pat. No. 5,647,979, Liao et al., U.S. Pat. No. 5,935,429,and Liao et al., U.S. Pat. No. 6,423,666.

The ligands are linked to the chromatography matrix via the spacer X¹.Linkage to the chromatography matrix will depend on the chromatographymatrix used and the chemical group to be linked to the chromatographymatrix. Ligands can be linked to the chromatography matrix by performinga reaction between the ligand and a functional group on thechromatography matrix. For chromatography matrices that do not have asuitable functional group, the chromatography matrix is reacted with asuitable activating reagent to create a suitable functional group towhich the ligand can be attached. Reductive amination, epoxide chemistryor azalactone chemistry are examples of chemistries acting on aldehyde,epoxide, or azalactone functional groups, respectively. For example, achromatography matrix functionalized with an aldehyde or a ketone groupcan be used to link the chromatography matrix to an amine group in theligand. In some embodiments, the chromatography matrix comprises a diol,which is converted to an aldehyde, e.g., by conversion with NaIO₄. Aprimary amine of the ligand can be linked to the created aldehyde on thechromatography matrix by a reductive amination reaction by the schemebelow. In this scheme, the spacer X is —O—CH₂—CH₂—. In this and othersynthetic schemes in this disclosure, the box represents the matrix andall coupling chemistry is shown separately.

In some embodiments, the chromatography matrix comprises an epoxidegroup and a primary amine in the ligand is linked to the epoxide groupvia epoxide chemistry by the scheme below. In this scheme, the spacer Xis —O—CH₂—CH(OH)—CH₂—.

In some embodiments, the chromatography matrix comprises an azlactonering and a primary amine in the ligand is linked to the azlactone ringby the scheme below. In this scheme, the spacer X is —CO—NH—C(CH3)₂—CO—.

In some embodiments, the chromatography matrix comprises a diol and aprimary amine is linked to an —OH group by activating the resin with twoactivating reagents, allylglydicylether (AGE) and bromine, by the schemebelow. In this scheme, the spacer X is—O—CH₂—CH(CH₂—OH)—(O—CH₂—CH(OH)—CH₂)₂—.

In certain embodiments, the chromatography matrix comprises an —OH groupand a primary amine is linked to the —OH group by activating the resinwith epichlorohydrin by the scheme below. In this scheme, the spacer Xis —O—CH₂—CH(OH)—CH₂—.

In some embodiments, the chromatography matrix comprises an —OH groupand a primary amine is linked to the —OH group by activating the resinwith 1,4 butanedioldiglycidyl ether by the scheme below. In this scheme,the spacer X is —O—CH₂—CH(OH)—CH₂—O—CH₂—CH₂—CH₂—CH₂—O—CH₂—CH(OH)—CH₂—.

Other activating reagents include, but are not limited to,epibromohydrin, bis-epoxides such as; halogen-substituted aliphaticcompounds such as di-chloro-propanol, divinyl sulfone;carbonyldiimidazole; aldehydes such as glutaric dialdehyde; quinones;cyanogen bromide; periodates such as sodium-meta-periodate;carbodiimides; chloro-triazines such as cyanuric chloride; sulfonylchlorides such as tosyl chlorides and tresyl chlorides; N-hydroxysuccinimides; 2-fluoro-1-methylpyridinium toluene-4-sulfonates;oxazolones; maleimides; pyridyl disulfides; and hydrazides.

Other spacers can include, but are not limited to, —O—CH₂—,—O—CH₂—CH₂—CH₂—, —O—CH₂—CH₂—CH₂—CH₂—,—O—CH₂—CH₂—CH(CH₂—OH)—(O—CH₂—CH₂—CH(OH)—CH₂)₂—, and—O—CH₂—CH₂—CH(OH)—CH₂—CH₂—.

The chromatography matrix can be utilized in any conventionalconfiguration, including packed columns and fluidized or expanded-bedcolumns, monoliths or porous membranes, and by any conventional method,including batchwise modes for loading, washes, and elution, as well ascontinuous or flow-through modes. In some embodiments, a column canrange in diameter from 1 cm to 1 m, and in height from 1 cm to 30 cm ormore.

Depending on the pH of the chromatography mobile phase buffer, anynitrogen in the ligand can be protonated and; thus, can carry a positivecharge.

Methods

Also provided are methods of purifying a target biomolecule. In anembodiment, the method comprises contacting a sample comprising thebiomolecule to a chromatography resin , thereby separating thebiomolecule from a contaminant. The resulting purified biomolecule issubsequently collected. In some embodiments, the target biomolecule is amonomeric antibody and the method comprises purifying the monomericantibody from aggregated antibodies in the sample.

The chromatographic resins are useful for purifying target moleculesusing anionic exchange (i.e., where the ligand is positively charged)and hydrophobic mixed mode chromatography. The conditions can beadjusted so as to run the chromatography in bind-elute mode orflow-through mode.

Protein preparations to which the methods can be applied can includeunpurified or partially purified proteins, including but not limited to,antibodies (e.g. IgG, IgM) and non-antibody proteins from natural,synthetic, or recombinant sources. Unpurified protein preparations, forexample, can come from various sources including, but not limited to,plasma, serum, ascites fluid, milk, plant extracts, bacterial lysates,yeast lysates, or conditioned cell culture media. Partially purifiedprotein preparations can come from unpurified preparations that havebeen processed by at least one chromatography, precipitation, otherfractionation step, or any combination of the foregoing. In someembodiments, the chromatography step or steps employ any method,including but not limited to size exclusion, affinity, anion exchange,cation exchange, protein A affinity, hydrophobic interaction,immobilized metal affinity chromatography, or hydroxyapatitechromatography. The precipitation step or steps can include salt orpolyethylene glycol (PEG) precipitation, or precipitation with organicacids, organic bases, or other agents. Other fractionation steps caninclude but are not limited to crystallization, liquid:liquidpartitioning, or membrane filtration.

As will be appreciated in the art, load, wash and elution conditions foruse in the mixed mode chromatography will depend on the specificchromatography matrix/ligand used.

In some bind-elute mode embodiments, loading (i.e., binding theantibodies or non-antibody protein to the chromatography resin), andoptionally washing, is performed at a pH above 7, e.g., between 7-8 or7-9. Some exemplary bind-elute conditions are:

binding condition: 0-1000 mM NaCl or 100-300 mM NaCl, pH 6.5-8.5 in anappropriate buffer (e.g., Tris, Bis-Tris or phosphate);elution condition: 1-1000 mM NaCl or 0-150 mM NaCl, pH 3-8.5 or 3.0-5.0,using an appropriate buffer having sodium acetate, citrate, arginine, orglycine.

Optionally, the chromatography resin can be washed under conditions suchthat some components of the sample are removed from the chromatographyresin but the target biomolecules remain immobilized on the resin. Insome embodiments, the target biomolecule is subsequently eluted bylowering the salt concentration and/or reducing the pH of the solutionin contact with the resin.

Alternatively, the sample can be applied in flow through mode in whichsome components of the sample are immobilized to the chromatographyresin but the target biomolecules flow through (i.e., flow passed) thechromatography resin, and is collected. Some exemplary flow throughconditions are 0-150 mM NaCl, pH 4.0-8.0; appropriate buffers caninclude, e.g., 2-(N-morpholino)ethanesulfonic acid (IVIES), Bis-Tris,sodium acetate or citrate-phosphate.

EXAMPLES

The following examples are provided by way of illustration only and notby way of limitation. Those of skill in the art will readily recognize avariety of non-critical parameters that could be changed or modified toyield essentially the same or similar results.

Example 1—Preparation of Chromatography Resins having the ligands ofTable 2

TABLE 2 Structure of Chromatography Number Resin (Spheres represent fromChromatography matrix and Table 1 spacer X¹) 1

2

11

12

13

14

15

For each of the ligands in Table 2, UNOSPHERE® Diol (20 mL), a copolymerof 3-allyloxy-1,2-propanediol and vinyl pyrrolidinone, crosslinked withN,N′-methylenebisacrylamide and with a diol density of 200-300 μmol/mL,was used in the form of spherical beads. For each ligand, beads weresuspended in 20 mL of either 0.1M sodium acetate or water. Sodiumperiodate was added to a concentration within the range of 50 to 100 mM,and the resulting mixtures were incubated at room temperature(approximately 70° F. (21° C.)) for 3-24 hours. The reactions resultedin conversion of the diol groups to aldehyde groups in the range of150-250 μmol/mL. Each of the resulting aldehyde-functionalized beads wastransferred to a 20-mL column where each resin was washed with 100 mL ofwater.

For each ligand, twenty milliliters of aldehyde-functionalized beads wasthen suspended in 20 ml of 0.20M sodium phosphate containing 0.6 g ofN-(4-aminophenyl)guanidine at pH 7.0. After these mixtures wereincubated (shaking, 200 rpm) at room temperature for 15 minutes, 200 mgNaBH3CN was then added and the reactions were allowed to continue for3-20 hours. The ligand concentration in each reaction was determined tobe in the range of 25-200 mM. At the end of the reactions, each resinwas transferred to a 20 ml column, washed with 3 CV of water followed by1-2 CV of 0.1N HCl, and then washed with 5 CV water. The ligand densityfor all the resins was in the range of 25-100 μmol/ml.

Example 2—Purification of Antibodies Using the resins of Example 1 andFlow Through Mode

Each of the resins listed in Table 2 (generated as described above) arepacked into a 7 mm (i.d.)×5.5 cm column and is equilibrated with 20 mMsodium acetate containing 75 mM NaCl at pH 4.5. 750 μl of a 2.0 mg/mlsolution of a monoclonal IgG antibody containing 15-20% aggregatedantibodies is applied to the column at a flow rate of 2 ml/minute. Theantibody flows through each of the columns. To remove contaminants thatbind to each resin, each column is washed in a 10 ml gradient ofequilibration buffer to elution buffer with 20 mM sodium acetate at pH4.5, followed by a 10 ml isocratic elution with elution buffer. Thecollected antibody in the flow-through fractions of each column isanalyzed by size exclusion high performance liquid chromatography(HPLC-SEC) to determine the content of aggregated antibody. No antibodyaggregates are detected in the antibody flow-through fractions for eachcolumn.

Example 3—Purification of Antibodies Using the Resins of Example 1 andBind-Elute Mode (Gradient Elution)

Each of the resins listed in Table 2 is packed into a 7 mm (i.d.)×5.5 cmcolumn and equilibrated with 20 mM Tris-HCl buffer containing 300 mMNaCl, pH 8.5. 500 μl of 6.0 mg/ml solution of a monoclonal IgG antibodycontaining 5-10% aggregated antibodies is applied to each column at aflow rate of 2 ml/minute. For each column, the antibody is eluted in a10 ml gradient of equilibration buffer to elution buffer with 20 mMsodium acetate containing 150 mM NaCl at pH 4.5, followed by a 30 mlisocratic elution with elution buffer. The collected antibody elutionfractions of each column are analyzed by size exclusion high performanceliquid chromatography (HPLC-SEC) to determine the content of aggregatedantibody in the elution fractions. No antibody aggregates are detectedin the antibody elution fractions of any of the columns.

Example 4—Purification of Antibodies Using the Resins of Example 1 andBind-Elute Mode (Step Elution and Gradient Elution)

Each resin in Table 2 was tested in bind-elute mode for the ability toremove aggregates from impure antibody solutions and/or for the abilityof a pure antibody (i.e., no aggregates) to bind to the resin. Variousantibodies were tested.

Materials

-   1. Chromatography resins listed in Table 2.-   2. Samples containing one of the following monoclonal antibodies    (mAbs). The amount of mAb in the samples was determined by Bradford    assay using bovine IgG as a standard.    -   a. Humanized anti-vascular endothelial growth factor monoclonal        antibody (mAb1)—about 15 mg of mAb1 in 7 mL crude Chinese        hamster ovary (CHO) cell harvest (or about 2 mg/mL). The crude        CHO cell harvest contained 5-10% aggregated mAb1.    -   b. Anti-human epidermal growth factor receptor 2 monoclonal        antibody (mAb2)—about 15 mg of mAb2 in 5 mL crude Chinese        hamster ovary (CHO) cell harvest (or about 3 mg/mL). The crude        CHO cell harvest contained 5-10% aggregated mAb2.    -   c. Purified mAb3—about 15 mg in 3 ml binding buffer (or about 5        mg/mL).    -   d. Purified mAb4—about 15 mg in 3 ml binding buffer (or about 5        mg/mL).-   3. Columns: 7 mm (i.d.)×5.5 cm.-   4. Binding/wash buffer:    -   a. 1×PBS—10 mM phosphate, 137 mM sodium chloride (NaCl), and 2.7        mM potassium chloride, pH 7.2 or 7.8.    -   b. Modified 1×PBS (higher NaCl concentration)—10 mM phosphate,        300 mM sodium chloride (NaCl), and 2.7 mM potassium chloride, pH        7.2-   5. Elution buffer: 50 mM sodium acetate (NaOAc), pH 5.0 or 5.4 or    100 mM glycine, pH 3.-   6. Stripping buffer: 1 N sodium hydroxide (NaOH).

Methods: For each resin in Table 2, the resin was packed into a columnand equilibrated with the binding/wash buffer listed in Table 3. Samplescontaining mAb (see Table 3 for the sample applied to each resin) wereapplied to the columns and the columns were washed with binding/washbuffer. For step elution, the monomeric or purified mAb was eluted with10 column volumes (CV) of elution buffer. For gradient elution (i.e.,resin 2 tested with mAb1), the antibody was eluted with a 15 CV gradientof binding/wash buffer to elution buffer, followed by 5 CV isocraticelution with elution buffer. All the columns were cleaned or strippedwith stripping buffer after the mAb was eluted.

The collected antibody elution fractions of each column were analyzed bysize exclusion high performance liquid chromatography (HPLC-SEC) todetermine the percent aggregate content of antibody in the elutionfractions. The percent monomer content for the samples was determined bysubtracting the percent aggregate content from 100% and is listed inTable 3.

In Table 3, “˜” symbolizes “about”.

TABLE 3 Number from Binding and Monomer content Table 1 Antibody Washbuffer Elution Conditions (%) 1 mAb1 1× PBS, pH Step elution: 10 CV 50~99 7.2 mM NaOAc, pH 5.4 2 mAb1 1× PBS, pH Step elution: 10 CV 50 ~977.2 mM NaOAc, pH 5.4 mAb1 1× PBS, pH Gradient elution: 0-100% ~97 7.8 50mM NaOAc, Ph 5.0, 15 CV, then hold for 5 CV mAb2 1× PBS, pH Stepelution: 10 CV 50 ~97 7.8 mM NaOAc, pH 5.0 Purified 1× PBS, pH Stepelution: 10 CV 50 None eluted with step mAb3 7.8 mM NaOAc, pH 5.0elution; Eluted with 100 mM glycine pH 3 (monomer content ~75%) Purified1× PBS, pH Step elution: 10 CV 50 ~97 mAb4 7.8 mM NaOAc, pH 5.0 11 mAb11× PBS, pH Step elution: 10 CV 50 Monomer content not 7.2 mM NaOAc, pH5.4 determined, assumed the same as Resin 2 (~97) 12 Purified 1× PBS, pHStep elution: 10 CV 50  0 mAb4 7.2 mM NaOAc, pH 5.4 Modified 1× Stepelution: 10 CV 50 Eluted in both the flow PBS, pH mM NaOAc, pH 5.4through and eluate; 7.2, 300 monomer content in mM NaCl combined FT andeluate ~100 13 mAb1 1× PBS, pH Step elution: 10 CV 50 ~97 7.2 mM NaOAc,pH 5.4 14 mAb1 1× PBS, pH Step elution: 10 CV 50 Eluted in both the FT7.2 mM NaOAc, pH 5.4 and eluate; monomer content in combined FT andeluate ~94 15 mAb1 1× PBS, pH Step elution: 10 CV 50 Eluted in both theFT 7.2 mM NaOAc, pH 5.4 and eluate; monomer content in combined FT andeluate ~94

Results: The results in Table 3 show that, by varying the binding andelution conditions, any of the resins can be used to purify antibodies(i.e., to remove aggregates). For example, monomeric mAb1 was bound toResins 1, 2, and 11 with 1×PBS, pH 7.2 or pH 7.8 and more than 97%monomeric mAb1 was eluted by step elution with 50 mM NaOAc, pH 5.4 or pH5.0. For resin 2, gradient elution (i.e., 0-100% 50 mM NaOAc, pH 5.0)was also used to purify mAb1: the results show that more than 97%monomeric mAb1 was eluted. Additionally, for resins 14 and 15, monomericmAb1 was collected in the flow through with 1×PBS, pH 7.2 binding bufferand 50 mM NaOAc, pH 5.4 elution buffer.

All patents, patent applications, and other published referencematerials cited in this specification are hereby incorporated herein byreference in their entirety.

Additional Disclosure and Claimable Subject Matter

Item 1. A chromatography resin having the formula:

Chromatography matrix-(X¹)-L-Ar-(X²)-Y

-   -   or a tautomer or an anionic salt thereof,    -   wherein:        -   X¹ is a spacer;        -   X² is C₁ to C₅ alkyl, C₃ or C₅ cycloalkyl, or absent;        -   L is NR⁸, O, or S wherein R⁸ is hydrogen or C₁ to C₆ alkyl;        -   Ar is a 6- to 10-membered aryl mono or bicylic ring            optionally substituted with up to four C₁ to C₃            unsubstituted alkyl or C₃ to C₆ branched alkyl; and        -   Y is selected from the group consisting of:

-   -   -   wherein:            -   R¹, R², R³, R⁴, R⁵, R⁶, and R₇ are each independently                hydrogen or C₁ to C₆ alkyl;            -   if Y is

R² is optionally joined to R³ to form a 4- to 7-membered heterocycle orR³ is optionally joined to R⁴ to form a 4- to 7-membered heterocycle;

-   -   -   -   if Y is

R¹ is optionally joined to R² to form a 4- to 7-membered heterocycle andR³ is optionally joined to R⁴ to form a 4- to 7-membered heterocycle;and

-   -   -   -   if Y is

R⁵ is optionally joined to R⁶ to form a 4- to 7-membered heterocycle orR⁶ is optionally joined to R⁷ to form a 4- to 7-membered heterocycle.

Item 2. The chromatography resin of item 1,

-   -   wherein:        -   X² is C₁-C₃ alkyl or absent;        -   L is NR⁸, O, or S wherein R⁸ is hydrogen or C₁ to C₃ alkyl;        -   Ar is phenyl or napthyl optionally substituted with up to            four C₁ to C₃ unsubstituted alkyl; and        -   Y is selected from the group consisting of:

-   -   -   wherein:            -   R¹, R², R³, R⁴, R⁵, R⁶, and R₇ are each independently                hydrogen or C₁ to C₄ alkyl;            -   if Y is

R² is optionally joined to R³ to form a 4- to 6-membered heterocycle orR³ is optionally joined to R⁴ to form a 4- to 6-membered heterocycle;

-   -   -   -   if Y is

R¹ is optionally joined to R² to form a 4- to 6-membered heterocycle andR³ is optionally joined to R⁴ to form a 4- to 6-membered heterocycle;and

-   -   -   -   if Y is

R⁵ is optionally joined to R⁶ to form a 4- to 6-membered heterocycle orR⁶ is optionally joined to R⁷ to form a 4- to 6-membered heterocycle.

Item 3. The chromatography resin of item 2, wherein:

-   -   X¹ is a is selected from the group consisting of —O—CH₂—,        —O—CH₂—CH₂—, —O—CH₂—CH₂—CH₂—, —O—CH₂—CH₂—CH₂—CH₂—,        —O—CH₂—CH(CH₂—OH)—(O—CH₂—CH(OH)—CH₂)₂—,        —O—CH₂—CH₂—CH(CH₂—OH)—(O—CH₂—CH₂—CH(OH)—CH₂)₂—, CH(OH)—CH₂—,        —O—CH₂—CH₂—CH(OH)—CH₂—CH₂—,        —O—CH₂—CH(OH)—CH₂—O—CH₂—CH₂—CH₂—CH₂—O—CH₂—CH(OH)—CH₂—, and        —CO—NH—C(CH₃)₂—CO—;    -   X² is —CH₂— or absent;    -   L is NR⁸ wherein R⁸ is hydrogen or —CH₃;    -   Ar is phenyl optionally substituted with one or two C₁ to C₂        unsubstituted alkyl; and    -   Y is selected from the group consisting of:

-   -   wherein:        -   R¹, R², R³, R⁴, R⁵, R⁶, and R⁷ are each independently            hydrogen or C₁ to C₃ alkyl.

Item 4. The chromatography resin of item 1 or 2, wherein Y is

and R² is joined to R³ to form a 4- or 5-membered heterocycle.

Item 5. The chromatography resin of item 1 or 2, wherein Y is

and R³ is joined to R⁴ to form a 4- to 6-membered heterocycle.

Item 6. The chromatography resin of item 1 or 2, wherein Y is

and R⁵ is joined to R⁶ to form a 4- or 5-membered heterocycle or R⁶ isjoined to R⁷ to form a 4- or 5-membered heterocycle.

Item 7. The chromatography resin of any one of items 1-6, wherein R¹-R⁷are each independently hydrogen, C₁ or C₂ alkyl.

Item 8. The chromatography resin of item 7, wherein R¹-R⁷ are eachindependently hydrogen or —CH₃.

Item 9. The chromatography resin any previous item, wherein X¹ isselected from the group consisting of —O—CH₂—, —O—CH₂—CH₂—,—O—CH₂—CH₂—CH₂—, —O—CH₂—CH₂—CH₂—CH₂—, and—O—CH₂—CH(CH₂—OH)—(O—CH₂—CH(OH)—CH₂)₂—.

Item 10. The chromatography resin of any previous item, wherein Ar isunsubstituted.

Item 11. The chromatography resin of any one of items 1-10, wherein ifAr is phenyl, chromatography matrix-(X¹)-L- is at a para or metaposition relative to (X²)-Y.

Item 12. The chromatography resin of any one of items 1-11, whereinchromatography matrix-(X¹)-L-Ar-(X²)-Y is any one of the structures inthe right-most column of Table 1.

Item 13. The chromatography resin of any one of items 1-12, wherein theanionic salt is hydrochloride or sulfate.

Item 14. A chromatography resin prepared by reacting any one of theligands of Table 1 with a chromatography matrix by any one of reductiveamination, epoxide chemistry, or azalactone chemistry.

Item 15. The chromatography resin of item 14, wherein the chromatographymatrix comprises an aldehyde group and any one of the ligands of Table 1is reacted with the chromatography matrix by reductive amination.

Item 16. The chromatography resin of item 14, wherein the chromatographymatrix comprises an epoxide group and any one of the ligands of Table 1is reacted with the chromatography matrix by epoxide chemistry.

Item 17. The chromatography resin of any one of items 14-16 whereinprior to reacting the chromatography matrix with the ligand thechromatography matrix is reacted with allylglydicylether and bromine;1,4-butanedioldiglycidyl; or epichlorohydrin.

Item 18. The chromatography resin of item 17, wherein the chromatographymatrix comprises an —OH group and it is reacted with allylglydicyletherand bromine.

Item 19. A method of purifying a biomolecule, the method comprising:

-   -   contacting a sample comprising the biomolecule to a        chromatography resin of any one of items 1-18, thereby        separating the biomolecule from a contaminant; and        -   collecting a purified biomolecule.

Item 20. The method of item 19, wherein the purified biomolecule is aprotein.

Item 21. The method of item 20, wherein the protein is an antibody.

Item 22. The method of any one of items 19-21, wherein the samplecomprises a monomeric antibody and antibody aggregates, the methodcomprises separating the monomeric antibody from the antibodyaggregates, and the purified biomolecule comprises the monomericantibody.

Item 23. The method of item 22, wherein the contacting step comprisesimmobilizing the monomeric antibody to the chromatography matrix and thecollecting step comprises eluting the monomeric antibody from thechromatography matrix.

Item 24. The method of item 23, wherein the monomeric antibody is elutedwith a pH gradient of a buffer in contact with the ligand from about 7-9to about 3-6.

Item 25. The method of item 22, wherein the contacting step comprisesflowing the monomeric antibody through the chromatography matrix and thecollecting step comprises collecting the monomeric antibody in the flowthrough.

1. (canceled)
 2. A chromatography configuration comprising a packedcolumn, fluidized column, expanded-bed column, monolith or porousmembrane comprising a chromatography resin having the formula:Chromatography matrix-(X₁)-L-Ar-(X₂)-Y or a tautomer or an anionic saltthereof, wherein: X¹ is a spacer; X² is C₁ to C₅ alkyl, C₃ or C₅cycloalkyl; L is NR⁸, O, or S wherein R⁸ is hydrogen or C₁ to C₆ alkyl;Ar is a 6- to 10-membered aryl mono or bicylic ring optionallysubstituted with up to four C₁ to C₃ unsubstituted alkyl or C₃ to C₆branched alkyl; and Y is selected from the group consisting of:

wherein: R¹, R², R³, R⁴, R⁵, R⁶, and R⁷ are each independently hydrogenor C₁ to C₆ alkyl; if Y is

 R² is optionally joined to R³ to form a 4- to 7-membered heterocycle orR³ is optionally joined to R⁴ to form a 4- to 7-membered heterocycle; ifY is

 R¹ is optionally joined to R² to form a 4- to 7-membered heterocycleand R³ is optionally joined to R⁴ to form a 4- to 7-memberedheterocycle; and if Y is

 R⁵ is optionally joined to R⁶ to form a 4- to 7-membered heterocycle orR⁶ is optionally joined to R⁷ to form a 4- to 7-membered heterocycle. 3.The chromatography configuration of claim 2, wherein: X² is C₁-C₃ alkyl;L is NR⁸, O, or S wherein R⁸ is hydrogen or C₁ to C₃ alkyl; Ar is phenylor napthyl optionally substituted with up to four C₁ to C₃ unsubstitutedalkyl; and Y is selected from the group consisting of:

wherein: R¹, R², R³, R⁴, R⁵, R⁶, and R⁷ are each independently hydrogenor C₁ to C₄ alkyl; if Y is

 R² is optionally joined to R³ to form a 4- to 6-membered heterocycle orR³ is optionally joined to R⁴ to form a 4- to 6-membered heterocycle; ifY is

 R¹ is optionally joined to R² to form a 4- to 6-membered heterocycleand R³ is optionally joined to R⁴ to form a 4- to 6-memberedheterocycle; and if Y is

 R⁵ is optionally joined to R⁶ to form a 4- to 6-membered heterocycle orR⁶ is optionally joined to R⁷ to form a 4- to 6-membered heterocycle. 4.The chromatography configuration of claim 2, wherein: X¹ is a isselected from the group consisting of —O—CH₂—, —O—CH₂—CH₂—,—O—CH₂—CH₂—CH₂—, —O—CH₂—CH₂—CH₂—CH₂—,—O—CH₂—CH(CH₂—OH)—(O—CH₂—CH(OH)—CH₂)₂—,—O—CH₂—CH₂—CH(CH₂—OH)—(O—CH₂—CH₂—CH(OH)—CH₂)₂—, —O—CH₂—CH(OH)—CH₂—,—O—CH₂—CH₂—CH(OH)—CH₂—CH₂—,—O—CH₂—CH(OH)—CH₂—O—CH2—CH₂—CH₂—CH₂—O—CH₂—CH(OH)—CH₂—, and—CO—NH—C(CH3)₂—CO—; X² is —CH₂—; L is NR⁸ wherein R⁸ is hydrogen or—CH₃; Ar is phenyl optionally substituted with one or two C₁ to C₂unsubstituted alkyl; and Y is selected from the group consisting of:

wherein: R¹, R², R³, R⁴, R⁵, R⁶, and R⁷ are each independently hydrogenor Ci to C3 alkyl.
 5. The chromatography configuration of claim 2,wherein R¹-R⁷ are each independently hydrogen, C₁ or C₂ alkyl.
 6. Thechromatography configuration of claim 5, wherein R¹-R⁷ are eachindependently hydrogen or —CH₃.
 7. The chromatography configuration ofclaim 2, wherein X¹ is selected from the group consisting of —O—CH₂—,—O—CH₂—CH₂—, —O—CH₂—CH₂—CH₂—, —O—CH₂—CH₂—CH₂—CH₂—, and—O—CH₂—CH(CH₂—OH)—(O—CH₂—CH(OH)—CH₂)₂—.
 8. The chromatographyconfiguration of claim 2, wherein Ar is unsubstituted.
 9. Thechromatography configuration of claim 2, wherein if Ar is phenyl,chromatography matrix-(X¹)-L- is at a para or meta position relative to(X²)-Y.
 10. The chromatography configuration of claim 2, whereinchromatography matrix-X¹-L-Ar-X²-Y is any one of the followingstructures: Num- Structure of Chromatography Resin (spheres berrepresent matrix and spacer X¹) 2

3

4

5

6

7a

7b

8a

8b

9

10

11

12

13

14

15

16

17

18

19

20

21

or 22


11. The chromatography configuration of claim 2, wherein the anionicsalt is hydrochloride or sulfate.
 12. A method of purifying abiomolecule, the method comprising: contacting a sample comprising thebiomolecule to a chromatography configuration of claim 2, therebyseparating the biomolecule from a contaminant; and collecting a purifiedbiomolecule.
 13. The method of claim 12, wherein the purifiedbiomolecule is a protein.
 14. The method of claim 13, wherein theprotein is an antibody.
 15. The method of claim 12, wherein the samplecomprises a monomeric antibody and antibody aggregates, the methodcomprises separating the monomeric antibody from the antibodyaggregates, and the purified biomolecule comprises the monomericantibody.
 16. The method of claim 15, wherein the contacting stepcomprises immobilizing the monomeric antibody to the chromatographymatrix and the collecting step comprises eluting the monomeric antibodyfrom the chromatography matrix.
 17. The method of claim 16, wherein themonomeric antibody is eluted with a pH gradient of a buffer in contactwith the ligand from about 7-9 to about 3-6.
 18. The method of claim 15,wherein the contacting step comprises flowing the monomeric antibodythrough the chromatography matrix and the collecting step comprisescollecting the monomeric antibody in the flow through.
 19. Achromatography configuration comprising a chromatography resin havingthe formula:Chromatography matrix-(X¹)-L-Ar-(X²)-Y or a tautomer or an anionic saltthereof, wherein: X¹ is a spacer; X² is C₁ to C₅ alkyl, C₃ or C₅cycloalkyl or is absent; L is NR⁸, O, or S wherein R8 is hydrogen or C₁to C₆ alkyl; Ar is a 6- to 10-membered aryl mono or bicylic ringoptionally substituted with up to four C₁ to C₃ unsubstituted alkyl orC₃ to C₆ branched alkyl; and Y is selected from the group consisting of:

 wherein R¹ and R⁴ are each independently hydrogen or C₁ to C₆ alkyl andR² is joined to R³ to form a 4- or 5-membered heterocycle;

 wherein R¹ and R² are each independently hydrogen or C₁ to C₆ alkyl andR³ is joined to R⁴ to form a 4- to 6-membered heterocycle; and

 wherein R¹, R², R³, and R⁴ are each independently hydrogen or C₁ to C₆alkyl and R⁵ is joined to R⁶ to form a 4- or 5-membered heterocycle orR¹, R², R³, R⁴, and R⁵ are each independently hydrogen or C₁ to C₆ alkylR⁶ is joined to R⁷ to form a 4- or 5-membered heterocycle.
 20. Thechromatography configuration of claim 19, wherein Y is

wherein R¹ and R² are each independently hydrogen or C₁ to C₆ alkyl andR³ is joined to R⁴ to form a 4- to 6-membered heterocycle.
 21. Thechromatography configuration of claim 19, wherein Y is

 wherein R¹, R², R³, R⁴, and R⁷ are each independently hydrogen or C₁ toC₆ alkyl and R⁵ is joined to R⁶ to form a 4- or 5-membered heterocycleor R¹, R², R³, R⁴, and R⁵ are each independently hydrogen or C₁ to C₆alkyl and R⁶ is joined to R⁷ to form a 4- or 5-membered heterocycle. 22.The chromatography configuration of claim 19, wherein Y is

wherein R¹ and R⁴ are each independently hydrogen or C₂ to C₆ alkyl andR² is joined to R3 to form a 4- or 5-membered heterocycle.
 23. A methodof purifying a biomolecule, the method comprising: contacting a samplecomprising the biomolecule to a chromatography configuration of claim19, thereby separating the biomolecule from a contaminant; andcollecting a purified biomolecule.
 24. The method of claim 23, whereinthe purified biomolecule is a protein.
 25. The method of claim 24,wherein the protein is an antibody.
 26. The method of claim 23, whereinthe sample comprises a monomeric antibody and antibody aggregates, themethod comprises separating the monomeric antibody from the antibodyaggregates, and the purified biomolecule comprises the monomericantibody.
 27. The method of claim 26, wherein the contacting stepcomprises immobilizing the monomeric antibody to the chromatographymatrix and the collecting step comprises eluting the monomeric antibodyfrom the chromatography matrix.
 28. The method of claim 27, wherein themonomeric antibody is eluted with a pH gradient of a buffer in contactwith the ligand from about 7-9 to about 3-6.
 29. The method of claim 26,wherein the contacting step comprises flowing the monomeric antibodythrough the chromatography matrix and the collecting step comprisescollecting the monomeric antibody in the flow through.